Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients with Chronic Abdominal Pain Associated with Crohn's Disease

Bruce R. Yacyshyn*, Stephen Hanauer, Preston Klassen, Brett A. English, Kathe Stauber, Charles F. Barish, Kye Gilder, Stewart Turner, Peter D.R. Higgins

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients with Chronic Abdominal Pain Associated with Crohn's Disease'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Medicine and Dentistry

Agricultural and Biological Sciences